ArticleJournal of multidisciplinary healthcare2026
Frailty After Transarterial Chemoembolization for Hepatocellular Carcinoma: A Cross-Sectional Study of Incidence and Associated Factors.
Article in Journal of multidisciplinary healthcare, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the incidence of and factors associated with frailty in hepatocellular carcinoma (HCC) patients after transarterial chemoembolization (TACE), with the objective to inform future personalized managements. Methods: In this cross-sectional study conducted from January to October 2025, HCC patients undergoing TACE at a tertiary hospital in Suzhou were selected by convenience sampling and completed a general information questionnaire. The Fried frailty phenotype, Nutritional Risk Screening 2002 tool, and Barthel Index for activities of daily living were comprehensively evaluated between postoperative days 1 and 4 following TACE. Factors associated with frailty after TACE were identified via univariate and multivariate logistic regression analyses. Results: Among the 312 included patients, 87 (27.9%) patients and 225 (72.1%) patients were in the frailty and non-frailty groups, respectively. Univariate analysis revealed statistically significant differences in age, sex, nutritional risk, Barthel Index, systemic immune-inflammatory index (SII), and hemoglobin level between the two groups ( Conclusion: A significant number of HCC patients could have frailty after TACE. Advanced age, female sex, poor nutrition, low Barthel Index, high SII, and low hemoglobin level were associated with frailty in these patients. Further prospective trials are required to identify modifiable variables and evaluate interventions to prevent or reduce frailty in HCC patients undergoing TACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.